ArticleMovement disorders clinical practice2019
Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories.
Abstract read
In one paragraph
Article in Movement disorders clinical practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 6 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Huntington's disease in MENAT: systematic review and meta-analysis of prevalence, clinical features, and genetics.Journal of neurology · 2025Pooled it
- Variation in the reported prevalence of Huntington's disease: a systematic review and guide to interpretation.Journal of neurology · 2025Pooled it
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- Quality of life, health-related quality of life, and associated factors in Huntington's disease: a systematic review.Journal of neurology · 2023Pooled it
- Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta-Analysis.Movement disorders : official journal of the Movement Disorder Society · 2022Pooled it
- Remote smartphone-based spoken language screening predicts clinical markers in Huntington's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Developing prognostic models that predict onset and progression rates in genetic neurodegenerative diseases: perspectives of healthcare professionals in genetic counselling.Orphanet journal of rare diseases · 2026Article
- Blood-based biomarkers for Alzheimer's disease: influence of kidney function.Alzheimer's research & therapy · 2026Article
- Using a Brief Body Sway Assessment Device to Track Balance Differences across the Huntington's Disease Integrated Staging System Spectrum.Movement disorders clinical practice · 2026Article
- Dysphagia in Huntington's Disease: An Evaluation of Swallowing Disturbance across the HD-ISS Staging Spectrum.Movement disorders clinical practice · 2025Article
- Natural products proposed for the management of Huntington's disease (HD): a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Neural Mechanisms of Object Location Memory in Huntington's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Improving the Clinical Diagnostic Criteria for Genetically Confirmed Adult-Onset Huntington Disease: Considering Nonmotor Presentations.Neurology. Clinical practice · 2025Article
- Revised Diagnostic Criteria for Huntington Disease: What's It Gonna Take?Neurology. Clinical practice · 2025Article
- Shifting focus from ideality to reality: a qualitative study on how quality of life is defined by premanifest and manifest Huntington's disease gene expansion carriers.Orphanet journal of rare diseases · 2024Article
- Racial Disparities in Time to Huntington Disease Diagnosis in North America: An ENROLL-HD Analysis.Neurology. Clinical practice · 2024Article
- Cognition and movement in neurodegenerative disorders: a dynamic duo.Neural regeneration research · 2024Article
- Dynamic undirected graphical models for time-varying clinical symptom and neuroimaging networks.Statistics in medicine · 2024Article
- Cognitive reserve involves decision making and is associated with left parietal and hippocampal hypertrophy in neurodegeneration.Communications biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Christopher A RossDepartments of Psychiatry, Neurology, Neuroscience, and Pharmacology and Huntington's Disease Center Johns Hopkins University School of Medicine Baltimore MD USA.
Ralf ReilmannGeorge Huntington Institut, Head, European HD Network (EHDN) Huntington Center University of Munster Munster Germany.ORCID https://orcid.org/0000-0002-5904-9517
Francisco CardosoDepartment of Neurology in the Movement Disorders Unit, Neurology Service Internal Medicine Department of the Federal University of Minas Gerais Belo Horizonte MG Brazil.ORCID https://orcid.org/0000-0003-0808-0116
Elizabeth A McCuskerNeurology Department, Huntington Disease Service Westmead Hospital and Sydney University Medical School Sydney Australia.
Claudia M TestaVirginia Commonwealth University Richmond VA USA.
Julie C StoutInstitute of Cognitive and Clinical Neurosciences, School of Psychological Sciences Monash University Victoria Australia.
Blair R LeavittDepartment of Medical Genetics and Centre for Molecular Medicine and Therapeutics The University of British Columbia Vancouver Canada.
Zhong PeiThe First Affiliated Hospital Sun Yat-Sen University Guangzhou China.
Bernhard LandwehrmeyerDepartment of Neurology University Hospital of Ulm Ulm Germany.
Asuncion MartinezHD Community Member.
Jamie LeveyCure HD Initiative (CHDI) Management/CHDI Foundation Princeton NJ USA.
Teresa SrajerHD Community Member.
Jee BangDepartments of Neurology and Psychiatry, and Huntington's Disease Center Johns Hopkins University School of Medicine Baltimore MD USA.
Sarah J TabriziHuntington's Disease Centre, University College London Queen Square Institute of Neurology London United Kingdom.
Funding
Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1MValidation of Novel Pathogenic Post-Translational Modifications of Huntingtin, and of Modifying Enzymes as Therapeutic Targets for Huntington's DiseaseR01NS086452 · NINDS · JOHNS HOPKINS UNIVERSITY · PI ROSS, CHRISTOPHER A · 2014 to 2023
$6.2MNCATS NIH HHS UL1 TR002649NINDS NIH HHS R01 NS086452Wellcome Trust 200181/Z/15/Z
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.